BioArctic AB logo

BIOA B - BioArctic AB Share Price

SEK85.95 -1.1  -1.2%

Last Trade - 10:34am

Sector
Healthcare
Size
Mid Cap
Market Cap £670.7m
Enterprise Value £581.9m
Revenue £7.04m
Position in Universe 363rd / 1772
Bullish
Bearish
Unlock BIOA B Revenue
Momentum
Relative Strength (%)
1m -3.38%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 41.6 105.6 140.7 714 281.8 59.7 120.8 +61.4%
+2,063 -75.6 +1,844 -76.8
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, BioArctic AB revenues decreased 79% to SEK54M. Net loss applicable to common stockholders totaled SEK55.3M vs. income of SEK105.6M. Revenues reflect Milestone Payments segment decrease from SEK173.4M to SEK0K, Research Collaborations segment decrease of 34% to SEK54M, Asia (Region) segment decrease of 86% to SEK22.5M, Europe (Region) segment decrease of 66% to SEK31.5M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BIOA B Revenue Unlock BIOA B Revenue

Net Income

BIOA B Net Income Unlock BIOA B Revenue

Normalised EPS

BIOA B Normalised EPS Unlock BIOA B Revenue

PE Ratio Range

BIOA B PE Ratio Range Unlock BIOA B Revenue

Dividend Yield Range

BIOA B Dividend Yield Range Unlock BIOA B Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIOA B EPS Forecasts Unlock BIOA B Revenue
Profile Summary

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Public Since October 12, 2017
No. of Shareholders: 9,435
No. of Employees: 45
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 88,059,985
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BIOA B Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BIOA B
Upcoming Events for BIOA B
Frequently Asked Questions for BioArctic AB
What is the BioArctic AB share price?

As of 10:34am, shares in BioArctic AB are trading at SEK85.95, giving the company a market capitalisation of £670.7m. This share price information is delayed by 15 minutes.

How has the BioArctic AB share price performed this year?

Shares in BioArctic AB are currently trading at SEK85.95 and the price has moved by 37.66% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioArctic AB price has moved by 49.51% over the past year.

What are the analyst and broker recommendations for BioArctic AB?

Of the analysts with advisory recommendations for BioArctic AB, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioArctic AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will BioArctic AB next release its financial results?

BioArctic AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the BioArctic AB dividend yield?

BioArctic AB does not currently pay a dividend.

Does BioArctic AB pay a dividend?

BioArctic AB does not currently pay a dividend.

When does BioArctic AB next pay dividends?

BioArctic AB does not currently pay a dividend.

How do I buy BioArctic AB shares?

To buy shares in BioArctic AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioArctic AB?

Shares in BioArctic AB are currently trading at SEK85.95, giving the company a market capitalisation of £670.7m.

Where are BioArctic AB shares listed? Where are BioArctic AB shares listed?

Here are the trading details for BioArctic AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: BIOA B
What kind of share is BioArctic AB?

Based on an overall assessment of its quality, value and momentum, BioArctic AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioArctic AB share price forecast 2020?

Shares in BioArctic AB are currently priced at SEK85.95. At that level they are trading at 80.75% discount to the analyst consensus target price of 0.00.

Analysts covering BioArctic AB currently have a consensus Earnings Per Share (EPS) forecast of -1.23 for the next financial year.

How can I tell whether the BioArctic AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioArctic AB. Over the past six months, the relative strength of its shares against the market has been 24.15%. At the current price of SEK85.95, shares in BioArctic AB are trading at 10.58% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioArctic AB PE Ratio?

We were not able to find PE ratio data for BioArctic AB.

Who are the key directors of BioArctic AB?

BioArctic AB's management team is headed by:

Wenche Rolfsen - CHM
Ivar Verner - VCH
Ewa Bjorling - IND
Hans Ekelund - IND
Par Gellerfors - DRC
Lars Lannfelt - FDR
Mikael Smedeby - IND
Eugen Steiner - IND
Gunilla Osswald - CEO
Oskar Bosson - VPR
Johanna Falting - VPR
Jan Mattsson - CFO
Mikael Moge - VPR
Christer Moller - CSO
Nora Sjodin - VPR
Who are the major shareholders of BioArctic AB?

Here are the top five shareholders of BioArctic AB based on the size of their shareholding:

Demban AB Corporation
Percentage owned: 30.72% (22.6m shares)
Ackelsta AB Corporation
Percentage owned: 20.48% (15.1m shares)
Fjärde AP-Fonden Pension Fund
Percentage owned: 5.43% (4.00m shares)
Tredje AP Fonden Pension Fund Portfolio
Percentage owned: 5.17% (3.81m shares)
Tredje AP Fonden Pension Fund
Percentage owned: 5.17% (3.81m shares)
Similar to BIOA B
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.